MicroRNA Regulation of Human Herpesvirus Latency

Siyu Chen, Yue Deng, Dongli PanViruses 2022 · DOI

TL;DR

Human herpesviruses, notorious for their lifelong latent infections, employ microRNAs (miRNAs) to meticulously control the delicate balance between lytic replication and latency. This review synthesizes current knowledge on how both viral and host miRNAs orchestrate this complex dance, offering insights into potential therapeutic strategies against persistent viral infections.

What Problem Does This Paper Address?

Herpesviruses are masters of evasion, establishing lifelong latent infections that can reactivate and cause disease, particularly in immunocompromised individuals. The key to their persistence lies in their ability to suppress viral replication during latency while maintaining their genome within host cells, poised for reactivation. Understanding the molecular mechanisms that govern this lytic-latent switch is crucial for developing effective treatments. This paper addresses the critical role of microRNAs (miRNAs) in regulating this complex process, exploring how these small RNA molecules, encoded by both the virus and the host, act as key players in maintaining viral latency.

Methods

This paper is a review, synthesizing existing research rather than presenting new experimental data. The authors draw upon a vast body of literature that has employed various molecular biology techniques to investigate miRNA function in herpesvirus latency. These methods likely include:

  • miRNA identification and profiling: Techniques such as small RNA sequencing (RNA-seq) and quantitative PCR (qRT-PCR) are used to identify and quantify viral and cellular miRNAs expressed during different stages of herpesvirus infection, particularly during latency.
  • Gene silencing assays: Co-transfection experiments and reporter assays are used to demonstrate the ability of specific miRNAs to repress the expression of viral or cellular target genes.
  • Mutational analysis: Creating viral mutants with deleted miRNA genes or altered miRNA target sites allows researchers to assess the functional importance of these miRNAs in viral replication and latency.
  • Cross-linking and immunoprecipitation (CLIP) techniques: Methods like PAR-CLIP and HITS-CLIP are employed to experimentally validate miRNA-target interactions in vivo.
  • In vivo models: Animal models (e.g., mice, guinea pigs) and cell culture models (e.g., neuronal cultures, B cells, hematopoietic progenitor cells) are used to study herpesvirus latency and reactivation in a more biologically relevant context.

Datasets

Not discussed in the paper. As a review, this paper synthesizes data from numerous previously published studies.

Key Insights and Ideas

  • miRNAs as Master Regulators: Herpesviruses have evolved sophisticated strategies to utilize miRNAs, both their own and those of the host, to tightly control the lytic-latent switch. This highlights the central role of post-transcriptional regulation in viral persistence.
  • Dual Targeting Strategy: Viral miRNAs don't just target viral genes; they also manipulate host cellular pathways. This dual approach allows viruses to both suppress their own replication and create a cellular environment conducive to latency.
  • Latency-Specific miRNA Expression: Many viral miRNAs are expressed at high levels specifically during latency, underscoring their critical role in maintaining this quiescent state.
  • Host miRNA Hijacking: Viruses actively exploit host miRNAs, often those expressed in specific cell types where latency is established (e.g., neurons), to their advantage.
  • Immune Evasion through miRNAs: Beyond suppressing viral replication, miRNAs are employed by herpesviruses to evade host immune responses, further ensuring their long-term survival.
  • Mimicry for Persistence: Some viral miRNAs mimic host miRNAs, allowing them to co-opt existing cellular networks that promote cell survival and proliferation, crucial for maintaining latent infections in dividing cells.
  • Therapeutic Potential: The intricate miRNA-mediated regulation of herpesvirus latency opens avenues for novel therapeutic interventions, potentially by using miRNA mimics or inhibitors.

Key Results

The review details numerous specific examples of miRNAs and their targets across different herpesvirus subfamilies (alpha-, beta-, and gammaherpesviruses). Key findings include:

  • HSV: Viral miRNAs like miR-H2-3p and miR-H4-5p directly target immediate-early viral genes (ICP0 and ICP34.5), repressing lytic replication. Neuron-specific host miRNA miR-138-5p also targets HSV ICP0, demonstrating host-virus cooperation.
  • HCMV: Viral miRNAs such as miR-UL112-3p target viral IE1 and IE2 proteins, and also cellular pathways involved in apoptosis and immune responses.
  • EBV: Viral miRNAs like miR-BART20-5p target key lytic replication proteins (ZTA and RTA). Host miRNAs like let-7a can influence EBV reactivation. Gammaherpesvirus miRNAs also promote B-cell proliferation and survival.
  • KSHV: Viral miRNAs target viral genes like ORF50 (RTA) and host pathways involved in apoptosis and immune signaling. KSHV miRNAs also mimic host miRNAs like miR-155-5p.

Limitations and Future Work

  • Limited Animal Models: The review highlights the challenge of studying latency for all herpesviruses due to the lack of suitable small animal models for many of them. Humanized mouse models and in vitro models are crucial but have limitations in fully recapitulating human infections.
  • Focus on Viral miRNAs: While host miRNAs are increasingly recognized, much of the research has focused on viral miRNAs. Future work should delve deeper into the roles of cellular miRNAs in herpesvirus latency.
  • Functional Redundancy: The authors note that many pathways are targeted by multiple miRNAs, making it difficult to pinpoint essential individual miRNAs. This redundancy poses a challenge for developing targeted therapies.
  • Delivery Challenges: Developing miRNA-based therapeutics faces significant hurdles in delivering RNA sequences effectively to latently infected cells, especially neurons.
  • Systematic Screening Needed: Functional screening using miRNA mimics or inhibitors has not been extensively performed for herpesvirus latency and is suggested as a promising future direction.
  • Therapeutic Combinations: Given miRNA redundancy, future therapeutic strategies might involve combinations of miRNAs or their inhibitors to effectively disrupt latency and prevent reactivation.

Summary updated

Abstract

Herpesviruses are ubiquitous human pathogens. After productive (lytic) infection, all human herpesviruses are able to establish life-long latent infection and reactivate from it. Latent infection entails suppression of viral replication, maintenance of the viral genome in infected cells, and the ability to reactivate. Most human herpesviruses encode microRNAs (miRNAs) that regulate these processes during latency. Meanwhile, cellular miRNAs are hijacked by herpesviruses to participate in these processes. The viral or cellular miRNAs either directly target viral transcripts or indirectly affect viral infection through host pathways. These findings shed light on the molecular determinants that control the lytic-latent switch and may lead to novel therapeutics targeting latent infection. We discuss the multiple mechanisms by which miRNAs regulate herpesvirus latency, focusing on the patterns in these mechanisms.
BibTeX
@inproceedings{chen2022microrna,
  author = {Siyu Chen and Yue Deng and Dongli Pan},
  title = {{MicroRNA Regulation of Human Herpesvirus Latency}},
  booktitle = {Viruses},
  year = {2022},
  doi = {10.3390/v14061215},
}
Figure